The 7 analysts offering 12-month price forecasts for Syros Pharmaceuticals Inc have a median target of 18.00, with a high estimate of 21.00 and a low estimate of 9.00. The median estimate represents a +280.55% increase from the last price of 4.73.
The current consensus among 8 polled investment analysts is to Buy stock in Syros Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.44
Reporting Date Nov 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.